Moexipril hydrochloride

BeschreibungMoexipril hydrochloride is a novel ACE inhibitor first marketed in the U.S.A. for the treatment of hypertension as a monotherapy and as a second-line therapy in combination with diuretics or calcium antagonists. Like other ACE inhibitors, moexipril is a prodrug that is converted in the liver to its diacid moexiprilat which is the active agent. Moexipril displays a higher in vitro inhibitory potency to ACE than enalapril although its effectiveness in reduction of blood pressure in hypertensive patients is similar to that seen with enalapril. It is orally active with a rapid onset and prolonged duration of action. Excellent tolerability has been reported. Moexipril is distinguished by its lower cost than other marketed ACE inhibitors.

VerwendenAngiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of quinapril